79 related articles for article (PubMed ID: 24136868)
1. Adjusting overall survival for treatment switches: commonly used methods and practical application.
Watkins C; Huang X; Latimer N; Tang Y; Wright EJ
Pharm Stat; 2013; 12(6):348-57. PubMed ID: 24136868
[TBL] [Abstract][Full Text] [Related]
2. The net benefit for time-to-event outcome in oncology clinical trials with treatment switching.
Fukuda M; Sakamaki K; Oba K
Clin Trials; 2023 Dec; 20(6):670-680. PubMed ID: 37455538
[TBL] [Abstract][Full Text] [Related]
3. Adverse events in single-arm clinical trials with non-fatal time-to-event efficacy endpoint: from clinical questions to methods for statistical analysis.
Tassistro E; Bernasconi DP; Valsecchi MG; Antolini L
BMC Med Res Methodol; 2024 Jan; 24(1):3. PubMed ID: 38172810
[TBL] [Abstract][Full Text] [Related]
4. Composite event-free-survival as an endpoint in oncology drug evaluation: Review and guidance perspectives from the Haute Autorité de Santé (HAS).
Lengliné E; Baba J; de Boissieu P; Beaufils A; Desbiolles A; Diatta T; Cochat P; Chevret S
Eur J Cancer; 2024 Jun; 204():114047. PubMed ID: 38653034
[TBL] [Abstract][Full Text] [Related]
5. On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies.
Unkel S; Amiri M; Benda N; Beyersmann J; Knoerzer D; Kupas K; Langer F; Leverkus F; Loos A; Ose C; Proctor T; Schmoor C; Schwenke C; Skipka G; Unnebrink K; Voss F; Friede T
Pharm Stat; 2019 Mar; 18(2):166-183. PubMed ID: 30458579
[TBL] [Abstract][Full Text] [Related]
6. Association of differential censoring with survival and suboptimal control arms among oncology clinical trials.
Hsu EJ; Lin TA; Dabush DR; McCaw Z; Koong A; Lin C; Abi Jaoude J; Patel R; Kouzy R; El Alam MB; Noticewala S; Yang Y; Sherry AD; Fuller CD; Thomas CR; Tang C; Msaouel P; Das P; Huang B; Tian L; Sun R; Lee JJ; Meirson T; Ludmir EB
J Natl Cancer Inst; 2024 Jun; 116(6):990-994. PubMed ID: 38331394
[TBL] [Abstract][Full Text] [Related]
7. Illustrating idiographic methods for translation research: moderation effects, natural clinical experiments, and complex treatment-by-subgroup interactions.
Ridenour TA; Wittenborn AK; Raiff BR; Benedict N; Kane-Gill S
Transl Behav Med; 2016 Mar; 6(1):125-34. PubMed ID: 27012260
[TBL] [Abstract][Full Text] [Related]
8. Current and Evolving Methods to Visualize Biological Data in Cancer Research.
Chia PL; Gedye C; Boutros PC; Wheatley-Price P; John T
J Natl Cancer Inst; 2016 Aug; 108(8):. PubMed ID: 27245079
[TBL] [Abstract][Full Text] [Related]
9. Emulating Trials and Quantifying Bias: The Convergence of Health Technology Assessment Agency Real-World Evidence Guidance.
Chen S; Tikhonovsky N; Dhanji N; Ramagopalan S
Value Health; 2024 Feb; 27(2):265-267. PubMed ID: 38135213
[No Abstract] [Full Text] [Related]
10. Adjusting survival time estimates to account for treatment switching in randomized controlled trials--an economic evaluation context: methods, limitations, and recommendations.
Latimer NR; Abrams KR; Lambert PC; Crowther MJ; Wailoo AJ; Morden JP; Akehurst RL; Campbell MJ
Med Decis Making; 2014 Apr; 34(3):387-402. PubMed ID: 24449433
[TBL] [Abstract][Full Text] [Related]
11. Methods for adjusting for bias due to crossover in oncology trials.
Ishak KJ; Proskorovsky I; Korytowsky B; Sandin R; Faivre S; Valle J
Pharmacoeconomics; 2014 Jun; 32(6):533-46. PubMed ID: 24595585
[TBL] [Abstract][Full Text] [Related]
12. Analyzing overall survival in randomized controlled trials with crossover and implications for economic evaluation.
Jönsson L; Sandin R; Ekman M; Ramsberg J; Charbonneau C; Huang X; Jönsson B; Weinstein MC; Drummond M
Value Health; 2014 Sep; 17(6):707-13. PubMed ID: 25236994
[TBL] [Abstract][Full Text] [Related]
13. Adjusting for treatment switching in randomised controlled trials - A simulation study and a simplified two-stage method.
Latimer NR; Abrams KR; Lambert PC; Crowther MJ; Wailoo AJ; Morden JP; Akehurst RL; Campbell MJ
Stat Methods Med Res; 2017 Apr; 26(2):724-751. PubMed ID: 25416688
[TBL] [Abstract][Full Text] [Related]
14. Treatment switching in oncology trials and the acceptability of adjustment methods.
Latimer NR
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):561-4. PubMed ID: 25893990
[TBL] [Abstract][Full Text] [Related]
15. Correcting for non-compliance in randomized non-inferiority trials with active and placebo control using structural models.
Wu Y; Zhao L; Hou Y; Li K; Zhou X
Stat Med; 2015 Mar; 34(6):950-65. PubMed ID: 25534903
[TBL] [Abstract][Full Text] [Related]
16. Impact of treatment changes on the interpretation of the Concorde trial.
White IR; Walker S; Babiker AG; Darbyshire JH
AIDS; 1997 Jul; 11(8):999-1006. PubMed ID: 9223734
[TBL] [Abstract][Full Text] [Related]
17. TREATMENT SWITCHING: STATISTICAL AND DECISION-MAKING CHALLENGES AND APPROACHES.
Latimer NR; Henshall C; Siebert U; Bell H
Int J Technol Assess Health Care; 2016 Jan; 32(3):160-6. PubMed ID: 27624982
[TBL] [Abstract][Full Text] [Related]
18. A Validation Study of the Rank-Preserving Structural Failure Time Model: Confidence Intervals and Unique, Multiple, and Erroneous Solutions.
Ouwens M; Hauch O; Franzén S
Med Decis Making; 2018 May; 38(4):509-519. PubMed ID: 29607730
[TBL] [Abstract][Full Text] [Related]
19. Improved two-stage estimation to adjust for treatment switching in randomised trials: g-estimation to address time-dependent confounding.
Latimer NR; White IR; Tilling K; Siebert U
Stat Methods Med Res; 2020 Oct; 29(10):2900-2918. PubMed ID: 32223524
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
